Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (241-250 of 404) with videos related to

Pageof 41
Sort By:
Journal of Hepatology|December 15, 2010
Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug usersJason Grebely, Gail V Matthews, Margaret Hellard, et al.
BMC Infectious Diseases|June 2, 2016
HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infectionFrançois M J Lamoury, Behzad Hajarizadeh, Elizabeth Keoshkerian, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 1, 2022
Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C StudyJoanne M Carson, Gregory J Dore, Andrew R Lloyd, et al.
Open Forum Infectious Diseases|March 31, 2025
Prevalence of Injection-Related Bacterial and Fungal Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysisAlice Wheeler, Jeffrey Masters, Alyssa Pradhan, et al.
Plos One|July 21, 2015
The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering AnalysisFrançois M J Lamoury, Brendan Jacka, Sofia Bartlett, et al.
Journal of Hepatology|February 13, 2016
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluationNatasha K Martin, Peter Vickerman, Gregory J Dore, et al.
The Journal of Infectious Diseases|June 11, 2016
Toll-like Receptor Expression and Signaling in Peripheral Blood Mononuclear Cells Correlate With Clinical Outcomes in Acute Hepatitis C Virus InfectionSwee Lin G Chen Yi Mei, Jodie Burchell, Narelle Skinner, et al.
Hepatology (Baltimore, Md.)|January 30, 2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, et al.
The Lancet. Global Health|March 30, 2023
Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic reviewSamantha Colledge-Frisby, Sophie Ottaviano, Paige Webb, et al.
The Lancet Regional Health. Western Pacific|August 7, 2023
Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysisSophy T F Shih, Qinglu Cheng, Joanne Carson, et al.
Pageof 41

Showing results (241-250 of 404) with videos related to

Sort By:
Pageof 41
Journal of Hepatology|December 15, 2010
Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug usersJason Grebely, Gail V Matthews, Margaret Hellard, et al.
BMC Infectious Diseases|June 2, 2016
HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infectionFrançois M J Lamoury, Behzad Hajarizadeh, Elizabeth Keoshkerian, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 1, 2022
Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C StudyJoanne M Carson, Gregory J Dore, Andrew R Lloyd, et al.
Open Forum Infectious Diseases|March 31, 2025
Prevalence of Injection-Related Bacterial and Fungal Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysisAlice Wheeler, Jeffrey Masters, Alyssa Pradhan, et al.
Plos One|July 21, 2015
The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering AnalysisFrançois M J Lamoury, Brendan Jacka, Sofia Bartlett, et al.
Journal of Hepatology|February 13, 2016
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluationNatasha K Martin, Peter Vickerman, Gregory J Dore, et al.
The Journal of Infectious Diseases|June 11, 2016
Toll-like Receptor Expression and Signaling in Peripheral Blood Mononuclear Cells Correlate With Clinical Outcomes in Acute Hepatitis C Virus InfectionSwee Lin G Chen Yi Mei, Jodie Burchell, Narelle Skinner, et al.
Hepatology (Baltimore, Md.)|January 30, 2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, et al.
The Lancet. Global Health|March 30, 2023
Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic reviewSamantha Colledge-Frisby, Sophie Ottaviano, Paige Webb, et al.
The Lancet Regional Health. Western Pacific|August 7, 2023
Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysisSophy T F Shih, Qinglu Cheng, Joanne Carson, et al.
Pageof 41